search for


Bile Acids and the Metabolic Disorders
Korean J Clin Pharm 2018;28(4):273-278
Published online December 31, 2018
© 2018 Korean College of Clinical Pharmacy.

Ji Hye Roh and Jeong-Hyun Yoon*

College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea
Correspondence to: Jeong-Hyun Yoon, College of Pharmacy, Pusan National University, 63 Beon-gil 2, Busandaehag-ro, Geumjeong-gu, Busan 46241, Republic of Korea Tel: +82-51-513-2804, Fax: +82-51-513-6754 E-mail:
Received November 30, 2018; Revised December 17, 2018; Accepted December 17, 2018.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Bile acids are major constituents of bile and known to help absorb dietary fat and fat-soluble vitamins in the gastrointestinal tract. In the past few decades, many studies have shown that bile acids not only play a role in fat digestion but also function as broad range of signal transduction hormones by binding to various receptors present in cell membranes or nuclei. Bile acid receptors are distributed in a wide range of organs and tissues in the human body. They perform multitudes of physiological functions with complex mechanisms. When bile acids bind to their receptors, they regulate fat and glucose metabolism in a tissue-specific way. In addition, bile acids are shown to inhibit inflammation and fibrosis in the liver. Considering the roles of bile acids as metabolic regulators, bile acids and their receptors can be very attractive targets in treating metabolic disorders. In the future, if roles of bile acids and their receptors are further clarified, they will be the novel target of drugs in the treatment of various metabolic diseases.
Keywords : Bile acid, metabolic disorder, receptor, metabolism

December 2018, 28 (4)
Full Text(PDF) Free

Social Network Service

Cited By Articles
  • CrossRef (0)

Funding Information